Zylox-Tonbridge Medical Technology Co., Ltd.

Zylox-Tonbridge Medical Technology Co., Ltd. is a prominent private equity firm specializing in investments within the medical device sector, focusing on companies with innovative technologies. The firm is headquartered in Hangzhou, Zhejiang Province, China, and has a significant presence in the Greater China region. It is listed on the Hong Kong Stock Exchange under the stock code 2190. The firm's investment strategy encompasses a broad spectrum of stages, including early-stage, growth, late-stage, pre-IPO, and buyout investments. Geographically, Zylox-Tonbridge has expanded its reach beyond China, with investments and partnerships in countries such as Indonesia, Ecuador, the United States, Germany, France, Italy, Spain, Turkey, Saudi Arabia, Argentina, Brazil, and South Africa. This global footprint reflects the firm's commitment to advancing medical technologies worldwide. Zylox-Tonbridge's portfolio is diverse, encompassing various industries within the medical sector, including medical devices, healthcare, biotechnology, pharmaceuticals, medical equipment, medical technology, healthtech, medtech, medical research, medical services, medical supplies, medical instruments, medical diagnostics, medical imaging, and medical equipment manufacturing. This extensive industry focus underscores the firm's dedication to supporting a wide range of medical innovations. In recent years, Zylox-Tonbridge has achieved significant milestones, such as the approval of its ZYLOX Unicorn® Suture-mediated Closure System by the National Medical Products Administration in China, marking a breakthrough in vascular puncture solutions. The firm has also entered into strategic partnerships, including a notable collaboration with Avinger, Inc., a U.S.-based medical device company, to expand disruptive optical coherence tomography (OCT) solutions for peripheral vascular interventions. These initiatives highlight Zylox-Tonbridge's proactive approach to fostering innovation and enhancing the accessibility of advanced medical technologies globally. Zylox-Tonbridge's investment philosophy centers on identifying and nurturing companies that demonstrate strong growth potential and a commitment to improving patient outcomes through technological advancements. By leveraging its extensive industry expertise and global network, the firm continues to play a pivotal role in shaping the future of the medical device industry, both within China and internationally.

Innovative medical device technologies, Strong growth potential, Commitment to improving patient outcomes, Technological advancements